US › Healthcare

Xenetic Biosciences Inc (XBIO)

US · Healthcare · Biotechnology

$2.81+5.64%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$806,923

Revenue YoY

+36.0%

Net profit

$-456,382

Profit YoY

+49.5%

EPS

$-0.20

Net margin

-56.6%

Key statistics

Market cap

$6.1M

Forward P/E

0.0

P/B

0.84

Book value

$3.23

EPS (TTM)

$-1.19

52-week high

$13.93

52-week low

$1.90

50-day MA

$2.91

200-day MA

$2.79

Beta

2.15

Analyst view

Analysts rate Xenetic Biosciences Inc a hold (0 buy, 1 hold, 0 sell out of 1) with an average price target of $40.00.

Shareholding

Insiders

15.77%

Institutions

7.42%

Largest institutional holders

Fund	Stake
Renaissance Technologies Corp	6.00%
Geode Capital Management, LLC	0.94%
Vanguard Capital Management, LLC	0.29%
JTC Employer Solutions Trustee Ltd	0.12%
Tower Research Capital LLC	0.04%
Harwood Advisory Group, LLC	0.00%
DRW Securities, LLC	0.00%
Morgan Stanley - Brokerage Accounts	0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Xenetic Biosciences Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.